ALTACE
What it isACE inhibitor; hypertension, heart failure and cardiovascular risk reduction.
Why this oneCardiovascular event reduction in high-risk patients without heart failure, which is a broader indication than most of the class carries.
What limits itCough, hyperkalemia and the hemodynamic creatinine rise. Contraindicated in pregnancy.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension | Adults (no diuretic) | 2.5 mg QD | 2.5-20 mg/day QD or divided BID | 20 mg/day |
| Reduce risk of MI/stroke/CV death | Adults | 2.5 mg QD x1 wk, then 5 mg QD x3 wk | 10 mg QD | 10 mg/day |
| Heart failure post-MI | Adults | 2.5 mg BID (1.25 mg BID if hypotensive) | 5 mg BID | 5 mg BID |
Titration HTN: reassess after 2-4 wks; HF post-MI: increase ~3 wks apart
Renal HTN & HF with renal impairment: initial 1.25 mg QD; adjust downward in moderate-severe impairment
Hepatic Impaired liver function may markedly elevate ramipril levels; use caution
Pregnancy Contraindicated implication — fetal renal toxicity, oligohydramnios, skull hypoplasia, death in 2nd/3rd trimester; discontinue when detected
Lactation Not recommended in nursing mothers
⚠ BOXED WARNING
Principal riskAngioedema and hyperkalemia
Cost, est. cash$5–$150/month
Generic entry2005
Legacy pregnancy categoryD
Defining liabilityHyperkalemia, kidney injury, angioedema, fetal toxicity and increased lithium exposure.

Open Ramipril in the interactive console ↗

